Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP

Abstract

Pleural effusion (PE) is the most frequent pulmonary complication of dasatinib, a tyrosine kinase inhibitor (TKI). Concurrent pericardial effusions have been reported in about one-third of the cases. In this study, we aimed to investigate ascites generation in chronic-phase chronic myeloid leukemia (CML-CP) patients developing PE under dasatinib.

Keywords

• ascites
• chronic myeloid leukemia
• chronic-phase chronic myeloid leukemia (cml-cp)
• dasatinib
• pleural effusion